{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:58:27Z","timestamp":1790452707258,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014164","name":"ProQR Therapeutics NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103001","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:39:07Z","timestamp":1783604347000},"page":"103001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ADAR RNA editing for cardiovascular disease: Targeting B4GALT1 to modulate lipid metabolism through reduced galactosyltransferase activity"],"prefix":"10.1016","volume":"37","author":[{"given":"Francesco","family":"De Chiara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6709-7554","authenticated-orcid":false,"given":"Eva","family":"Coll-de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galja","family":"Pletikapi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cnubben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emy","family":"Theunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne J.","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"van den Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.G.","family":"Princen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Yilmaz-Elis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjef J.","family":"De Kimpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3499-7542","authenticated-orcid":false,"given":"Gerard","family":"Platenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.omtn.2026.103001_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.abe0348","article-title":"Genetic and functional evidence links a missense variant in B4GALT1 to lower LDL and fibrinogen","volume":"374","author":"Montasser","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103001_bib3","article-title":"Metabolomics Ex\/GWAS in the Amish reveals novel insights into cardiometabolic disease pathways","author":"Jallow","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2026.103001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100595","article-title":"In-Depth Mass Spectrometry Analysis Reveals the Plasma Proteomic and N-Glycoproteomic Impact of an Amish-Enriched Cardioprotective Variant in B4GALT1","volume":"22","author":"Zhao","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.omtn.2026.103001_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/cvr\/cvaa252","article-title":"Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis","volume":"117","author":"Pirillo","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2026.103001_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1389106","article-title":"Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia","volume":"11","author":"Bashir","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.omtn.2026.103001_bib7","first-page":"429","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology","volume":"75","author":"Visseren","year":"2022","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.omtn.2026.103001_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1563384","article-title":"Cytosolic UDP-Gal biosynthetic machinery is required for dimerization of SLC35A2 in the Golgi membrane and its interaction with B4GalT1","volume":"12","author":"Wiertelak","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtn.2026.103001_bib9","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.2337\/db17-0323","article-title":"Hepatic GALE Regulates Whole-Body Glucose Homeostasis by Modulating Tff3 Expression","volume":"66","author":"Zhu","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.omtn.2026.103001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.b15-00716","article-title":"Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis","volume":"39","author":"Morita","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.omtn.2026.103001_bib12","first-page":"321","article-title":"Robust and Durable RNA Editing In Vivo with Axiomer\u2122 Editing Oligonucleotides in Non-Human Primates, ASGCT 27th Annual Meeting Abstracts","volume":"32","author":"Cnubben NHP","year":"2024","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.omtn.2026.103001_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/stcltm\/szaf016","article-title":"Emerging clinical applications of ADAR based RNA editing","volume":"14","author":"Rainaldi","year":"2025","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtn.2026.103001_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrm3383","article-title":"Vertebrate protein glycosylation: diversity, synthesis and function","volume":"13","author":"Moremen","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103001_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/glycob\/cww086","article-title":"Biological roles of glycans","volume":"27","author":"Varki","year":"2017","journal-title":"Glycobiology"},{"key":"10.1016\/j.omtn.2026.103001_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the Dependency of Cellular Protein Levels on mRNA Abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103001_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2026.103001_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1194\/jlr.RA119000419","article-title":"Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice","volume":"61","author":"Pouwer","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtn.2026.103001_bib19","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/hq1001.096651","article-title":"Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice","volume":"21","author":"van de Poll","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.omtn.2026.103001_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/dom.12252","article-title":"APOE\u22173Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome","volume":"16","author":"van den Hoek","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.omtn.2026.103001_bib21","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.107.142570","article-title":"Mouse models for atherosclerosis and pharmaceutical modifiers","volume":"27","author":"Zadelaar","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.omtn.2026.103001_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2014.05.931","article-title":"CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism","volume":"235","author":"Dong","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.omtn.2026.103001_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100753","article-title":"Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis","volume":"66","author":"Inia","year":"2025","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtn.2026.103001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105524","article-title":"Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE\u22173-Leiden.CETP mice","volume":"167","author":"Zhou","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omtn.2026.103001_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2015.03.089","article-title":"Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C\/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials","volume":"763","author":"K\u00fchnast","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omtn.2026.103001_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jimd.12200","article-title":"Reduced CETP glycosylation and activity in patients with homozygous B4GALT1 mutations","volume":"43","author":"van den Boogert","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omtn.2026.103001_bib27","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jpeds.2011.08.007","article-title":"B4GALT1-Congenital Disorders of Glycosylation Presents as a Non-Neurologic Glycosylation Disorder with Hepatointestinal Involvement","volume":"159","author":"Guillard","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omtn.2026.103001_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115302","article-title":"Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics","volume":"208","author":"Gil-Cabrerizo","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.103001_bib29","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2026.103001_bib30","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI118532","article-title":"Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice","volume":"97","author":"van Vlijmen","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103001_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.omtn.2023.05.016","article-title":"Lipid nanoparticle-encapsulated, chemically modified anti-adenoviral siRNAs inhibit hepatic adenovirus infection in immunosuppressed Syrian hamsters","volume":"32","author":"Geisler","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103001_bib31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0022-2275(20)42785-3","article-title":"Synthetic low and high fat diets for the study of atherosclerosis in the mouse","volume":"31","author":"Nishina","year":"1990","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omtn.2026.103001_bib32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.103001_bib33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1186\/1471-2164-14-778","article-title":"Finding the active genes in deep RNA-seq gene expression studies","volume":"14","author":"Hart","year":"2013","journal-title":"BMC Genom."},{"key":"10.1016\/j.omtn.2026.103001_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1748-7188-6-26","article-title":"ViennaRNA Package 2.0","volume":"6","author":"Lorenz","year":"2011","journal-title":"Algorithm Mol. Biol."},{"key":"10.1016\/j.omtn.2026.103001_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103001_bib36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.omtn.2026.103001_bib37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.omtn.2026.103001_bib38","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:03:50Z","timestamp":1788879830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126001721"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103001","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAR RNA editing for cardiovascular disease: Targeting B4GALT1 to modulate lipid metabolism through reduced galactosyltransferase activity","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103001"}}